Hemostemix Inc. (CVE:HEM – Get Free Report) was up 38.1% on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares traded hands during trading, an increase of 51% from the average daily volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The firm has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The firm’s fifty day moving average is C$0.09 and its 200-day moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Retail Stocks Investing, Explained
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Stock Dividend Cuts Happen Are You Ready?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
